Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IDEXX Laboratories, Inc. (IDXX) vs Visa Inc (V) Price & Performance

IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

IDEXX Laboratories, Inc. vs Visa Inc — how do they compare? IDEXX Laboratories, Inc. trades at $570.95 (market cap $46.22B), while Visa Inc trades at $358.86 (market cap $671.74B). The key difference: Visa Inc is far larger — about 14.5× IDEXX Laboratories, Inc.'s market cap, and Visa Inc pays a 0.74% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.

IDXXV
Market Cap
$46.22B$671.74B
Sector
HealthFinancials
52-Week High
$766.68$370.47
52-Week Low
$526.44$295.52
Enterprise Value
$47.12B$682.32B
Volume
10,431,336
Dividend Yield
0.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.

Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.

Visa Inc

Visa (V) trades at $358.92, down 0.66% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 and Q2 2026 earnings beats, with revenue growth from $40B in 2025 to a projected $44.5B in 2026. Analyst consensus is overwhelmingly bullish, with an 85.48% buy rating and a $426.31 price target, suggesting 19% upside. Recent news highlights Visa's AI initiatives, such as Intelligent Commerce Connect, to enhance payment efficiency.

Visa's outlook remains positive due to consistent earnings outperformance, high profit margins, and strategic AI adoption. Risks include rising fintech competition and regulatory pressures. The stock presents a long-term growth opportunity, supported by solid fundamentals and institutional confidence, though investors should monitor competitive and macroeconomic headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX

About Visa Inc

Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.

Read more on V